Sign inCreate account

Report workspace

Add to folder
NCT06919796NOT_YET_RECRUITINGanonymous

Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe

Sponsor

Source record

PharmaJet, Inc.

Phase

Source record

Phase 2

Modality

AI-normalized

RNA therapy

Target

AI-normalized

SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)

Indication / condition

AI-normalized

Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers

Intervention

Source record

COMIRNATY®

Source & freshness

Source record

NCT ID

NCT06919796

Original source

ClinicalTrials.gov

Source last updated

Apr 15, 2025

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06919796

Title

Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe

Sponsor

PharmaJet, Inc.

Status

NOT_YET_RECRUITING

Phase

Phase 2

Condition raw

Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2

Condition normalized

Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)

Target normalized

SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)

Interventions

COMIRNATY®

Public preview

Source record

PharmaJet, Inc. is investigating the immune response elicited by its mRNA COVID-19 vaccine, COMIRNATY®, administered via two different delivery methods: intradermal injection using the Tropis Needle-Free Injection System (NFIS) and traditional intramuscular injection. The study aims to assess the efficacy and safety of these delivery methods in a healthy adult population aged 18 to 50. Given the ongoing demand for effective COVID-19 vaccines and the potential advantages of needle-free delivery systems, successful outcomes could position PharmaJet favorably in the competitive vaccine market. The study's collaboration with Emory University may enhance credibility and provide access to additional research resources. However, the trial is not yet recruiting, which may delay market entry and impact investor confidence.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT06919796

Status

NOT_YET_RECRUITING

Phase

Phase 2

Sponsor

PharmaJet, Inc.

Executive brief

Investment-Ready Snapshot

PharmaJet, Inc. is investigating the immune response elicited by its mRNA COVID-19 vaccine, COMIRNATY®, administered via two different delivery methods: intradermal injection using the Tropis Needle-Free Injection System (NFIS) and traditional intramuscular injection. The study aims to assess the efficacy and safety of these delivery methods in a healthy adult population aged 18 to 50. Given the ongoing demand for effective COVID-19 vaccines and the potential advantages of needle-free delivery systems, successful outcomes could position PharmaJet favorably in the competitive vaccine market. The study's collaboration with Emory University may enhance credibility and provide access to additional research resources. However, the trial is not yet recruiting, which may delay market entry and impact investor confidence.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 15, 2025
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06919796

Indication

Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers

Modality

RNA therapy

Target

SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)

Intervention

COMIRNATY®

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.